Skip to content
2000
image of Apremilast in Psoriasis: Current Landscape and Perspectives

Abstract

Psoriasis is an immune-mediated skin disease manifested in more than 3% of Americans and over 125 million people worldwide. The inflammatory skin condition with an increased rate of keratinocyte turnover involves every level of the skin and exhibits various forms of the disease, including plaque, guttate, inverse, pustular, and erythrodermic psoriasis, as well as disease-associated conditions, such as psoriatic arthritis and nail psoriasis. Innovative treatment has highlighted the importance of Apremilast, an oral drug that belongs to the phosphodiesterase-4 (PDE4) class, which was approved by the FDA in 2014. Apremilast works by increasing the presence of cyclic adenosine monophosphate (cAMP) within cells, thereby affecting inflammatory processes and reducing the production of pathological cytokines. Randomized controlled trials have shown that it effectively treats moderately to severely affected plaque psoriasis and psoriatic arthritis, and it is safer than traditional systemic agents. The new perspective on the usage of ethosomes, niosomes, liposomes, and nanostructured lipid carriers in psoriasis treatment is based on emerging nanotechnology in drug delivery systems. These new formulations are designed to enhance the solubility and targeted release of Apremilast, thus providing an enhanced therapeutic effect. This review will discuss the basic mechanisms of the disease known as psoriasis, as well as the mode of operation, pharmacological properties, clinical trials, and pharmacokinetics of apremilast, particularly in relation to nanocarrier modification of this promising drug.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708351802250717104057
2025-07-29
2025-09-27

  • From This Site

    /content/journals/raiad/10.2174/0127722708351802250717104057
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches. Biomedicines 2021 9 11 1511 10.3390/biomedicines9111511 34829740
    [Google Scholar]
  2. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br. J. Dermatol. 2021 184 2 243 258 10.1111/bjd.19169 32358790
    [Google Scholar]
  3. Differences in clinical features and comorbid burden between HLA-C*06:02 carrier groups in >9,000 people with psoriasis. J. Invest. Dermatol. 2022 142 6 1617 1628 10.1016/j.jid.2021.08.446 34767815
    [Google Scholar]
  4. Current concepts of psoriasis immunopathogenesis. Int. J. Mol. Sci. 2021 22 21 11574 10.3390/ijms222111574 34769005
    [Google Scholar]
  5. Treatment of psoriasis: A comprehensive review of entire therapies. Curr. Drug Saf. 2020 15 2 82 104 10.2174/22123911MTAziOTU84 31994468
    [Google Scholar]
  6. The many variants of psoriasis. J. Fam. Pract. 2020 69 4 192 200 32437484
    [Google Scholar]
  7. Oral psoriasis—an overlooked entity: Current paradigms and future perspectives. Curr. Dermatol. Rep. 2024 13 2 85 94 10.1007/s13671‑024‑00424‑0
    [Google Scholar]
  8. Pustular psoriasis: The dawn of a new era. Acta Derm. Venereol. 2020 100 3 87 93 10.2340/00015555‑3388 31971600
    [Google Scholar]
  9. Artritis psoriásica. Med. Clín. 2022 159 1 40 46 10.1016/j.medcli.2022.01.024 35525675
    [Google Scholar]
  10. Challenge of nail psoriasis: An update review. Clin. Rev. Allergy Immunol. 2021 61 3 377 402 10.1007/s12016‑021‑08896‑9 34478047
    [Google Scholar]
  11. Comorbidities associated with psoriatic arthritis: Review and update. Clin. Immunol. 2020 214 108397 10.1016/j.clim.2020.108397 32229290
    [Google Scholar]
  12. A multivariate analysis of depression prevalence in psoriasis patients: A cohort study. Int. J. Environ. Res. Public Health 2022 19 4 2060 10.3390/ijerph19042060 35206248
    [Google Scholar]
  13. Environmental risk factors and epigenetic alternations in psoriasis. Ann. Agric. Environ. Med. 2020 27 3 335 342 10.26444/aaem/112107 32955211
    [Google Scholar]
  14. From bed to bench and back: TNF-α, IL-23/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis. Front. Pharmacol. 2021 12 672515 10.3389/fphar.2021.672515 34211394
    [Google Scholar]
  15. Pathogenesis of psoriasis and development of treatment. J. Dermatol. 2018 45 3 264 272 10.1111/1346‑8138.14139 29226422
    [Google Scholar]
  16. Emerging trends in combination strategies with phototherapy in advanced psoriasis management. Inflammopharmacology 2023 31 4 1761 1778 10.1007/s10787‑023‑01257‑2 37326755
    [Google Scholar]
  17. EMPATHY life in psoriasis: Embracing patients’ well-being in their journey of moderate-to-severe psoriasis. J. Clin. Med. 2024 13 15 4469 10.3390/jcm13154469 39124737
    [Google Scholar]
  18. Retrospective cohort study comparing efficacy and safety of pharmacological intervention and phototherapy in moderate to severe psoriasis patients in a real-world setting. Proceedings of the Latvian Academy of Sciences Section B Natural, Exact, and Applied Sciences 2024 78 2 141 146 10.2478/prolas‑2024‑0021
    [Google Scholar]
  19. Efficacy and safety of topical tacrolimus microemulsion applied twice daily in patients with mild to moderate scalp psoriasis. Dermatol. Ther. 2024 14 2 521 532 10.1007/s13555‑024‑01102‑6 38345680
    [Google Scholar]
  20. To analyze the efficacy of methotrexate and acitretin in psoriasis: Teaching hospital based study at West Bengal. J. Cardiovasc. Dis. Res. 2023 14 8 1778 1783
    [Google Scholar]
  21. Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis. Int. J. Pharm. 2023 631 122535 10.1016/j.ijpharm.2022.122535 36566826
    [Google Scholar]
  22. Recent advances in nanotechnology-based drug delivery systems for delivery of phytoconstituents with special emphasis on psoriasis management. INDIAN DRUGS 2024 61 4 7 15 10.53879/id.61.04.13939
    [Google Scholar]
  23. Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery. J. Drug Deliv. Sci. Technol. 2023 84 104548 10.1016/j.jddst.2023.104548
    [Google Scholar]
  24. Phosphodiesterase-4 inhibition in the management of psoriasis. Pharmaceutics 2023 16 1 23 10.3390/pharmaceutics16010023 38258034
    [Google Scholar]
  25. Apremilast: First pediatric approval. Paediatr. Drugs 2025 27 1 119 124 10.1007/s40272‑024‑00668‑0 39576565
    [Google Scholar]
  26. Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches. Drug Discov. Today 2023 28 2 103465 10.1016/j.drudis.2022.103465 36481585
    [Google Scholar]
  27. Current developments and perspectives in psoriasis. J. Dtsch. Dermatol. Ges. 2023 21 4 363 372 10.1111/ddg.15033
    [Google Scholar]
  28. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: Results from the APROACH observational prospective study. Rheumatol. Int. 2023 43 5 889 902 10.1007/s00296‑022‑05269‑z 36856816
    [Google Scholar]
  29. Recent advancements in topical anti-psoriatic nanostructured lipid carrier-based drug delivery. Int. J. Mol. Sci. 2023 24 3 2978 10.3390/ijms24032978 36769305
    [Google Scholar]
  30. The treatment of psoriasis via herbal formulation and nano-polyherbal formulation: A new approach. Bioimpacts 2024 15 30341 10.34172/bi.30341 40256226
    [Google Scholar]
  31. Pathogenesis of psoriasis in the “omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatol. Alergol. 2020 37 3 283 298 10.5114/ada.2020.96243 32774210
    [Google Scholar]
  32. Role of pro-inflammatory and anti-inflammatory cytokines in pathophysiology of psoriasis. Curr. Oral Health Rep. 2022 9 4 132 145 10.1007/s40496‑022‑00320‑1
    [Google Scholar]
  33. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J. Dermatol. 2021 48 6 750 760 10.1111/1346‑8138.15826 33650702
    [Google Scholar]
  34. Pathological role of excessive DNA as a trigger of keratinocyte proliferation in psoriasis. Clin. Exp. Immunol. 2020 202 1 1 10 10.1111/cei.13455 32415989
    [Google Scholar]
  35. Focus: Skin: Current developments in the immunology of psoriasis. Yale J. Biol. Med. 2020 93 1 97 110 32226340
    [Google Scholar]
  36. Adalimumab and methotrexate affect the concentrations of regulatory cytokines (interleukin‐10, transforming growth factor‐β1, and interleukin‐35) in patients with plaque psoriasis. Dermatol. Ther. 2020 33 6 e14153 10.1111/dth.14153 32770629
    [Google Scholar]
  37. Therapeutic development based on the immunopathogenic mechanisms of psoriasis. Pharmaceutics 2021 13 7 1064 10.3390/pharmaceutics13071064 34371756
    [Google Scholar]
  38. Cytokine alterations in psoriasis: An updated review. Expert Rev. Clin. Immunol. 2021 17 12 1323 1335 10.1080/1744666X.2022.2011720 34845948
    [Google Scholar]
  39. Role of Th17 cytokines in airway remodeling in asthma and therapy perspectives. Front Allergy 2022 3 806391 10.3389/falgy.2022.806391 35386663
    [Google Scholar]
  40. Phosphodiesterase-4 inhibition in psoriasis. Psoriasis. Psoriasis (Auckl.) 2021 11 21 29 10.2147/PTT.S303634 33763335
    [Google Scholar]
  41. Analytical method of Apremilast: A review. Asian J Pharm Anal 2020 10 1 44 47 10.5958/2231‑5675.2020.00010.1
    [Google Scholar]
  42. Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis. Indian Dermatol. Online J. 2020 11 1 51 57 10.4103/idoj.IDOJ_169_19 32055509
    [Google Scholar]
  43. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: The VIP-A phase 4, open-label, nonrandomized clinical trial. JAMA Dermatol. 2022 158 12 1394 1403 10.1001/jamadermatol.2022.3862 36129688
    [Google Scholar]
  44. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2022 86 1 77 85 10.1016/j.jaad.2021.07.040 34343599
    [Google Scholar]
  45. Harnessing the potential of fatty Acid-Surfactant-Based micellar gel for enhanced topical delivery of Apremilast in psoriasis treatment. Int. J. Pharm. 2024 655 124026 10.1016/j.ijpharm.2024.124026 38518872
    [Google Scholar]
  46. Apremilast in the treatment of plaque psoriasis: Differential use in psoriasis. Clin. Cosmet. Investig. Dermatol. 2022 15 395 402 10.2147/CCID.S266036 35300435
    [Google Scholar]
  47. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin. Gastroenterol. Hepatol. 2020 18 11 2526 2534 10.1016/j.cgh.2019.12.032 31926340
    [Google Scholar]
  48. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Joint Bone Spine 2023 90 3 105534 10.1016/j.jbspin.2023.105534 36706947
    [Google Scholar]
  49. Types of different psoriasis and its treatment. J. Emerg. Technol. Innov. Res. 2021 8 1 648 653
    [Google Scholar]
  50. Long‐term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations. Dermatol. Ther. 2020 33 3 e13440 10.1111/dth.13440 32306448
    [Google Scholar]
  51. Clinical implication of phosphodiesterase-4-inhibition. Int. J. Mol. Sci. 2022 23 3 1209 10.3390/ijms23031209 35163131
    [Google Scholar]
  52. Apremilast effectively inhibits TNFα‐induced vascular inflammation in human endothelial cells. J. Eur. Acad. Dermatol. Venereol. 2022 36 2 237 246 10.1111/jdv.17769 34699634
    [Google Scholar]
  53. Inhibition of phosphodiesterase-4 in psoriatic arthritis and inflammatory bowel diseases. Int. J. Mol. Sci. 2021 22 5 2638 10.3390/ijms22052638 33807944
    [Google Scholar]
  54. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and meta-analysis. Dermatol. Ther. 2023 13 2 437 451 10.1007/s13555‑022‑00877‑w 36609960
    [Google Scholar]
  55. Psoriatic arthritis: Pathogenesis and targeted therapies. Int. J. Mol. Sci. 2023 24 5 4901 10.3390/ijms24054901 36902329
    [Google Scholar]
  56. Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast. Front. Immunol. 2024 15 1459185 10.3389/fimmu.2024.1459185 39170613
    [Google Scholar]
  57. Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways. Eur. J. Pharmacol. 2023 947 175668 10.1016/j.ejphar.2023.175668 36958476
    [Google Scholar]
  58. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. J. Eur. Acad. Dermatol. Venereol. 2023 37 2 348 355 10.1111/jdv.18689 36300769
    [Google Scholar]
  59. Full prescribing information. New York, NY, USA Pfizer Inc. 2023
    [Google Scholar]
  60. Apremilast. In: Handbook of Systemic Drug Treatment in Dermatology. Boca Raton, FL CRC Press 2023 74 77
    [Google Scholar]
  61. The complexity and multiplicity of the specific cAMP phosphodiesterase family: PDE4, open new adapted therapeutic approaches. Int. J. Mol. Sci. 2022 23 18 10616 10.3390/ijms231810616 36142518
    [Google Scholar]
  62. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1). J. Eur. Acad. Dermatol. Venereol. 2020 34 8 1654 1665 10.1111/jdv.16684 32735076
    [Google Scholar]
  63. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of moderate-to-severe psoriasis. Clin. Pharmacokinet. 2024 63 2 137 153 10.1007/s40262‑023‑01341‑4 38280146
    [Google Scholar]
  64. Apremilast microemulsion as topical therapy for local inflammation: Design, characterization and efficacy evaluation. Pharmaceuticals 2020 13 12 484 10.3390/ph13120484 33371334
    [Google Scholar]
  65. An updated guide in the management of psoriasis for every practitioner. Int. J. Clin. Pract. 2021 75 8 e14290 10.1111/ijcp.14290 33928703
    [Google Scholar]
  66. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J. Am. Acad. Dermatol. 2023 88 1 29 39 10.1016/j.jaad.2022.07.002 35820547
    [Google Scholar]
  67. The efficacy and safety of apremilast in the management of psoriatic arthritis: A systematic review and meta-analysis. Cureus 2024 16 3 e55773 10.7759/cureus.55773 38590459
    [Google Scholar]
  68. Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Behçet’s syndrome. Am. J. Clin. Dermatol. 2023 24 5 809 820 10.1007/s40257‑023‑00783‑7 37316690
    [Google Scholar]
  69. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 2012 380 9843 738 746 10.1016/S0140‑6736(12)60642‑4 22748702
    [Google Scholar]
  70. Expert recommendations for the use of apremilast in psoriatic arthritis. Reumatol. Clín. 2023 19 1 34 44 10.1016/j.reumae.2022.01.001 35537933
    [Google Scholar]
  71. Real-world experience with apremilast in treating psoriasis. J. Cutan. Med. Surg. 2017 21 2 145 151 10.1177/1203475416676030 27846617
    [Google Scholar]
  72. Analytical methods for determination of apremilast from bulk, dosage form and biological fluids: A critical review. Crit. Rev. Anal. Chem. 2021 51 3 258 267 10.1080/10408347.2020.1718481 32024370
    [Google Scholar]
  73. Efficacy and safety of non-pharmacological and non-biological interventions: A systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann. Rheum. Dis. 2023 82 1 142 152 10.1136/ard‑2022‑223297 36261247
    [Google Scholar]
  74. Apremilast pharmacogenomics in Russian patients with moderate-to-severe and severe psoriasis. J. Pers. Med. 2020 11 1 20 10.3390/jpm11010020 33383665
    [Google Scholar]
  75. Phosphodiesterase 4 inhibitors: A review of current developments (2013–2021). Expert Opin. Ther. Pat. 2022 32 3 261 278 10.1080/13543776.2022.2026328 34986723
    [Google Scholar]
  76. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet’s syndrome. Expert Opin. Pharmacother. 2021 22 12 1533 1537 10.1080/14656566.2021.1939307 34218739
    [Google Scholar]
  77. Pharmacogenomics: An update on biologics and small-molecule drugs in the treatment of psoriasis. Genes 2021 12 9 1398 10.3390/genes12091398 34573380
    [Google Scholar]
  78. Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases. Inflamm Bowel Dis 2021 27 S38 62 (Suppl. 2) 10.1093/ibd/izab190 34791293
    [Google Scholar]
  79. Cytokines in psoriasis. Adv. Clin. Chem. 2021 100 171 204 10.1016/bs.acc.2020.04.004 33453865
    [Google Scholar]
  80. Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology. Life Sci. 2024 345 122565 10.1016/j.lfs.2024.122565 38521388
    [Google Scholar]
  81. Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment. Ther. Deliv. 2024 15 6 449 462 10.1080/20415990.2024.2343646 38888579
    [Google Scholar]
  82. Enhanced transdermal delivery of apremilast loaded ethosomes: Optimization, characterization and in vivo evaluation. J. Drug Deliv. Sci. Technol. 2024 91 105211 10.1016/j.jddst.2023.105211
    [Google Scholar]
  83. Apremilast loaded lyotropic liquid crystalline nanoparticles embedded hydrogel for improved permeation and skin retention: An effective approach for psoriasis treatment. Biomed. Pharmacother. 2023 162 114634 10.1016/j.biopha.2023.114634 37018989
    [Google Scholar]
  84. Solid lipid nanocarriers embedded hydrogel for topical delivery of apremilast: In-vitro, ex-vivo, dermatopharmacokinetic and anti-psoriatic evaluation. J. Drug Deliv. Sci. Technol. 2021 63 102442 10.1016/j.jddst.2021.102442
    [Google Scholar]
  85. Topical delivery of apremilast loaded nanostructured lipid carrier based hydrogel for psoriasis therapy. J. Pharm. Res. Int. 2021 33 28B 7 20 10.9734/jpri/2021/v33i28B31531
    [Google Scholar]
  86. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast. Dermatol. Ther. 2020 33 3 e13370 10.1111/dth.13370 32250507
    [Google Scholar]
  87. Apremilast: A review in oral ulcers of Behçet’s disease. Drugs 2020 80 2 181 188 10.1007/s40265‑019‑01253‑3 31933168
    [Google Scholar]
  88. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits 2015 8 Spec Feature 105 10 26629274
    [Google Scholar]
  89. Early discontinuation of apremilast in patients with psoriasis and gastrointestinal comorbidities: Rates and associated risk factors. Dermatol. Ther. 2023 13 9 2019 2030 10.1007/s13555‑023‑00975‑3 37517029
    [Google Scholar]
  90. Long‐term safety and tolerability of apremilast versus placebo in psoriatic arthritis: A pooled safety analysis of three phase III, randomized, controlled trials. ACR Open Rheumatol. 2020 2 8 459 470 10.1002/acr2.11156 32710493
    [Google Scholar]
  91. A study to investigate efficacy and safety of apremilast 30 mg twice daily (BID) in Chinese participants with moderate to severe plaque-type psoriasis (PsO) (ESSENCE). Patent NCT06122649 2023
  92. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 2015 73 1 37 49 10.1016/j.jaad.2015.03.049 26089047
    [Google Scholar]
  93. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2024 90 3 485 493 10.1016/j.jaad.2023.10.020 37852306
    [Google Scholar]
  94. Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium: Results from the observational OTELO study. Adv. Ther. 2022 39 2 1068 1080 10.1007/s12325‑021‑01981‑7 34977985
    [Google Scholar]
  95. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: A phase II open-label study. J. Drugs Dermatol. 2013 12 8 888 897 23986162
    [Google Scholar]
  96. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J. Dermatol. 2017 44 8 873 884 10.1111/1346‑8138.13829 28391657
    [Google Scholar]
  97. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J. Dermatolog. Treat. 2019 30 8 775 783 10.1080/09546634.2019.1577546 30747550
    [Google Scholar]
  98. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr. Med. Res. Opin. 2008 24 5 1529 1538 10.1185/030079908X301866 18419879
    [Google Scholar]
  99. Real-world apremilast use for treatment of plaque psoriasis in Italy: Patient perspective, characteristics, and clinical outcomes from the DARWIN Study. Adv. Ther. 2023 40 7 3021 3037 10.1007/s12325‑023‑02516‑y 37171752
    [Google Scholar]
  100. Evaluation of add on enstilar in patients using otezla for psoriasis. Patent NCT03587194 2024
  101. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J. Am. Acad. Dermatol. 2020 82 2 389 397 10.1016/j.jaad.2019.08.019 31408686
    [Google Scholar]
  102. A Study to assess benefits of apremilast in patients with moderate to severe chronic plaque psoriasis followed by dermatologists under real life settings in France (REALIZE). Patent NCT03757013 2021
  103. Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study. J. Dermatol. 2018 45 9 1053 1062 10.1111/1346‑8138.14504 29905383
    [Google Scholar]
  104. Defining and treating moderate plaque psoriasis: A dermatologist survey. J. Dermatolog. Treat. 2018 29 7 658 663 10.1080/09546634.2018.1443200 29502473
    [Google Scholar]
  105. Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione. Patent US8455536B2 2013
  106. Process for the preparation of apremilast. Patent US10774041B2 2020
/content/journals/raiad/10.2174/0127722708351802250717104057
Loading
Apremilast in Psoriasis: Current Landscape and Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/0127722708351802250717104057
/content/journals/raiad/10.2174/0127722708351802250717104057
/content/journals/raiad/10.2174/0127722708351802250717104057
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: phosphodiesterase-4 (PDE4) inhibitor ; Psoriasis ; drug delivery systems ; apremilast ; inflammation ; nanostructured lipid carriers ; psoriatic arthritis ; nanocarriers ; plaque psoriasis ; cyclic adenosine monophosphate (cAMP)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test